THE PARTNER FOR RAJASTHAN

T E S T

DETECT
CANCER EARLY,
SAVE LIVES.

BROUGHT TO YOU BY: EXCLUSIVE LICENSEE IN INDIA FOR:

 Background
Based on research done by the late Dr. VK Tripathi, brothers Anish and Ashish
Tripathi set up a diagnostic lab in Mumbai to launch HrC, a simple blood test
for the early detection of cancer. The HrC Test is named after their brother-in-
law, the late Himanshu Roy, IPS. They lost him to cancer in 2018.
Incidences of cancer are increasing globally across age-groups, genders,
and ethnicities; even as our modern lifestyle inadvertently exposes us to a
plethora of cancer-causing carcinogens. Globally, more than 50% cases of
cancer are detected at late-stage (i.e., stage III or IV), when the disease is
much stronger and fatalities more likely. Existing diagnostic technologies can
detect cancer post tumour formation only. HrC can conrm absence of cancer
or indicate likelihood of cancer presence even at its earliest stage, i.e., at
Stage 0, which is post cancer-initiation but before tumour-formation. This test
leverages a potential 18-month window between cancer initiation (genetic
mutations), and consequential tumour formation of a size which is clinically
detectable (See Fig 1: Gompertzian Model). We hope to move cancer from a
late-stage to an early-stage disease when it is weaker and innitely more
curable. Early detection can reduce the cost and time of treatment and
increase chances of survival signicantly.

Epigeneres Biotech
Epigeneres Biotech is a diagnostic and molecular-medicine company.
Epigeneres is the exclusive licensee of Tzar Labs (Singapore), for making this
test available in India. Epigeneres specialises in novel onco-biomarkers for
screening and early-detection of cancer. These onco-biomarkers are
associated with pathways and cellular processes such as cancer stemness,
microRNAs, metabolism, epigenetics, sustained growth signalling, etc.
Epigeneres has set up a state-of-the-art laboratory in Lower Parel (Mumbai),
which includes technology platforms like DDPCR, Flow Cytometry, Next
Generation Sequencing (NGS) and Optical Spectroscopy. It is GMP, GLP, ISO
9001:2015, HACCP certied.

Gompertzian Model+ of Tumor Growth

Fatality
1In
Un-detectable

100bn
u e)
Clinically

tea as
Pla Dise All others
10bn g (including Liquid
on
(Str Biopsy Cos.)
1bn
Tumour Cell Count

1bn

100mm
Rapid Cell
(18-month window)

10mn
Proliferation and THE
Stage Zero
Detectable

Tumour Growth
Clinically

1mn th
row
i a l G ase) T E S T
nit se
100k w I Di
Slo eak
(W
10k

Time

*Model developed by Benjamin Gompertz. **1 cm3 Tumour has 1 Billion Tumour Cells
About HrC Test
There is no global consensus on how cancer initiates despite several decades of research. More than 20 theories
have been put forth to explain cancer initiationmain being the Somatic Mutation Theory which suggests that
mutations in driver genes eventually lead to cancer.. Cancer Stem Cells (CSCs) have also been suggested to
initiate cancer and are responsible for metastasis and recurrence, since 1937. But there is ambiguity on the true
identity of these CSCs and whether they are transformed tissue-resident stem cells or arise by dedifferentiation
and reprogramming of differentiated cells. The breakthrough technology developed by Tzar & Epigeneres is
based on the hypothesis that very small embryonic-like stem cells (VSELS), residing in multiple tissues, undergo
epigenetic changes and get transformed into CSCs. In cancer patients, CSCs from impacted organs in the body
get mobilised into circulation in increased numbers and can be detected by the HrC test. Unique features of HrC
include (i) it is a pan-cancer screening test implying that conceptually it will detect most cancers in the body using
a simple, non-invasive approach (ii) CSCs get mobilised at very initial stage of cancer development unlike CTCs
and ctDNA which are detected only when the tumour becomes detectable through PET. It is crucial to detect and
treat cancer early in order to win the war against cancer and achieve objectives of the Cancer Moonshot initiative,
recently launched by US President Biden. It aims to reduce cancer deaths by at least 50% over the next 25 years
and improve quality of life for cancer survivors. India is also faced with a sizable cancer burden, which continues
to grow exponentially. HrC test has the potential to make a signicant impact and help reduce total cancer burden.
The HRC test utilises qPCR technology. It is based on a combination of certain genetic biomarkers that indicate
the key hallmarks of cancer. Since it is a non-invasive and safe test, it can be taken as frequently as deemed
necessary. The suggested frequency of testing depends on the HrC Score, which is a numeric indicator based on
the combination of genes and their relative expressions.
The HrC test can also assist Oncologists to monitor responsiveness during treatment protocols. It can also be
used to conrm remission more accurately as compared to all existing methods. This can eventually reduce the
frequency of invasive and potentially harmful tests like Positron Emission Tomography (PET), Computerised
Tomography (CT), etc.

The HrC Scale

Cancer
Risk of Cancer Presence
Absent

HrC Score <2 >2 4 6 8 10 10+

Absent Negligible Low Moderate High

Retest After 12 Months 6 - 9 Months 3 Months 1 Month Seek Medical

Advice

Through the HRC test we can:

1) Conrm Absence of Cancer
2) Indicate Likelihood of Cancer Presence (Negligible, Low, Medium, or High)
3) Monitor Responsiveness
4) Indicate Potential Remission/ Recurrence

Early detection can reduce cost and time of treatment, and improve the chances of survival signicantly and
eliminate uncertainty by testing for it proactively.
1000-subject Clinical Study
We conducted a double-blinded, CTRI registered, 1,000-subject clinical study in 2018, encompassing over 25
different types of cancer and investigated the potential of pluripotency markers for cancer diagnosis. In a prior
study of 120 known cancer patients, it was observed that pluripotency expression in peripheral blood correlated
well with the absence, imminence, or presence of cancer, and if present, it correlated with its indicative stage.
Based on these results, we developed a proprietary HrC scale wherein the fold-change of onco-biomarkers was
linked to patient status.
Types of Cancer Included in Study

Cancer Types Numbers Cancer Types Numbers

Breast Cancer 59 11.8% Testicular Cancer 16 3%

Liver Cancer 53 10.6% Thyroid Cancer 15 2.6%

Ovarian Cancer 48 9.6% Bile Duct Cancer 13 2.2%

Lung Cancer 41 8.2% Esophageal Cancer 11 2.2%
Leukemia 38 7.6% Endometrium 11 1.8%
Renal Cancer 31 6.2% Buccal Mucosa Cancer 9 1% TOTAL

Bladder Cancer 29 5.8% Gastric Cancer 5 1% 500

Prostate Cancer 23 4.6% Tongue Cancer 5 1%
Lymphoma Cancer 22 4.4% Retina Cancer 5 0.6%
Pancreatic Cancer 21 4.2% Penile Cancer 3 0.6%
Cervical Cancer 19 3.8% Ewing Sarcoma 3 0.4%

Colon Cancer 17 3.4% Gastrointestinal 2 0.2%

Osteosarcoma 16 3.2% Stromal Tumour(GIST) 1 0.1%

1000-subject Study Cancer Patient Breakdown

500 498 500 431

257
250 250
133
94
48 21
7 11
0 0

Non-Cancer High-Risk Stage I Stage II Stage III Stage IV Rx Naïve R0* On Rx

Cancer detected Cancer patient Cancer patient
but treatment has wherein tumour on treatment
not started surgically removed

National Reference laboratory

Plot No. 54, K.No. 10 & 12/2,
OUR LAB Manohar Vihar, New Pali Road,
Sangariya, Jodhpur 342005.
IN MUMBAI
( +91 95163 63951
info.jodhpur@acu-mdx.in

Epigeneres Biotech Private Limited

Todi Building, 1st Floor,
Mathuradas Mill Compound,
Senapati Bapat Marg,
Lower Parel, Mumbai 400013.

( +91 (22) 69778000

customercare@epigeneres.com
www.epigeneres.com